Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05862012
PHASE1

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Sponsor: Ichnos Sciences SA

View on ClinicalTrials.gov

Summary

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

Official title: A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2023-11-01

Completion Date

2027-07

Last Updated

2026-04-01

Healthy Volunteers

No

Interventions

DRUG

ISB 2001

Participants receive escalating doses of ISB 2001

DRUG

ISB 2001

Participants receive injection of ISB 2001 as determined in Part 1.

Locations (32)

Standford Cancer Institute

Palo Alto, California, United States

Sylvester Cancer Center

Miami, Florida, United States

Winship Cancer Institute

Atlanta, Georgia, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Montefiore Medical Center

The Bronx, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Tennessee Oncology

Nashville, Tennessee, United States

Virginia Commonwealth University (VCU)

Richmond, Virginia, United States

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Concord Hospital

Concord, New South Wales, Australia

Pindara Private Hospital

Benowa, Queensland, Australia

St. Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

Peter MacCallum Cancer Center

Melbourne, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

CHRU Lille

Lille, Hauts-de-France, France

CHU Poiters - Hospital la Miletrie

Poitiers, Nouvelle-Aquitaine, France

CHU de Nantes - Hotel Dieu

Nantes, Pays de la Loire Region, France

Groupe Hospitalier Pitie-Salpetriere

Paris, Île-de-France Region, France

Apollo Hospital International Limited

Gandhinagar, Gujarat, India

Health Care Global Enterprises Ltd.

Bangalore, Karnataka, India

Deenanath Mangeshkar Hospital and Research Centre

Pune, Maharashta, India

Apollo Cancer Centers

Hyderabad, Telangana, India

HCG Hospital

Bangalore, India

ASST Spedali Civili di Brescia

Brescia, Lombardy, Italy

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

Milan, Lombardy, Italy

Oslo University Hospital

Oslo, Oslo County, Norway

Instituto de Investigacion Biomedica de Salamanca (IBSAL)

Salamanca, Castile de Leon, Spain

Institut Catala de Oncologia (ICO)

Badalona, Catalonia, Spain

Hospital Clinic de Barcelona

Barcelona, Catalonia, Spain

Centro Integral Oncologici Clara Campal

Madrid, Madrid, Spain

Clinica Universidad de Nevarra

Pamplona, Navarre, Spain